Diagnostik und Therapie der Osteoporose

Literatur

• 1 Lunt M, Felsenberg D, Reeve J. et al . Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study.  J Bone Miner Res. 1997;  12 1883-1894
• 2 Roy D K, O'Neill T W, Finn J D. et al . Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS).  Osteoporos Int. 2003;  14 19-26
• 3 Melton L J. Epidemiology worldwide.  Endocrinol Metab Clin North Am. 2003;  32 1-13
• 4 Seeman E. Pathogenesis of bone fragility in women and men.  Lancet. 2002;  359 1841-1850
• 5 Rizzoli R, Bonjour J-P, Ferrari S. Osteoporosis, genetics and hormones.  J Molec Endocrinol. 2001;  26 79-94
• 6 Scheidt-Nave C, Baum E, Dören M. et al . DVO-Leitlinien Osteoporose bei postmenopausalen Frauen.  Osteologie. 2003;  12 63-91
• 7 Pientka L, Baum E, Kruse H-P. et al . DVO-Leitlinie Osteoporose des älteren Menschen.  Osteologie. 2003;  12 93-117
• 8 Brown J P, Josse R G. 2002 clinical practice guidelines for the diagnosis and managment of osteoporosis in Canada.  CMAJ. 2002;  167 (Suppl 10) S 1-S 34
• 9 Kanis J A. Diagnosis and osteoporosis and assessment of fracture risk.  Lancet. 2002;  359 1929-1936
• 10 Kanis J A, Johnell O, Oden A. et al . Intervention thresholds for osteoporosis.  Bone. 2002;  31 26-31
• 11 Johnell O, Odén A, De Laet C. et al . Biochemical indices of bone turnover and the assessment of fracture probability.  Osteoporos Int. 2002;  13 523-526
• 12 Kanis J A, Johnell O, Oden A. et al . Ten year probability of osteoporotic fractures according to BMD and diagnostic threshold.  Osteoporos Int. 2001;  12 989-995
• 13 Mittermeyer V, Müller V E, Allolio B. et al . DVO-Leitlinie Glukokortikoid-induzierte Osteoporose.  Osteologie. 2003;  12 119-137
• 14 Mohr A, Barkmann R, Mohr C. et al . [Quantitative ultrasound for the diagnosis of osteoporosis].  Fortschr Röntgenstr. 2004;  176 610-617
• 15 Gluer C C, Eastell R, Reid D M. et al . Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: The OPUS study.  J Bone Miner Res. 2004;  19 782-793
• 16 Garnero P, Delmas P D. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.  J Musculoskel Neuron Interact. 2004;  4 50-63
• 17 Seibel M J. Biochemical markers of bone remodeling.  Endocrinol Metab Clin North Am. 2003;  32 83
• 18 Eastell R, Barton I, Hannon R A. et al . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.  J Bone Miner Res. 2003;  18 1051-1056
• 19 Chapuy M C, Arlot M E, Duboeuf F. et al . Vitamin D3 and calcium to prevent hip fractures in elderly women.  N Engl J Med. 1992;  327 1637-1642
• 20 Dawson-Hughes B, Harris S S, Krall E A. et al . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older.  N Engl J Med. 1997;  337 670-676
• 21 Heikinheimo R J, Inkovaara J A, Harju E J. et al . Annual injection of vitamin D and fractures of aged bones.  Calc Tiss Int. 1992;  51 105-110
• 22 Porthouse J, Cockayne S, King C. et al . Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care.  Br Med J. 2005;  330 1003
• 23 Pfeifer M, Begerow B, Minne H W. Vitamin D and muscle function.  Osteoporos Int. 2002;  13 187-194
• 24 Bischoff H, Staehelin H B, Dick W. et al . Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial.  J Bone Miner Res. 2003;  18 343-351
• 25 Hulley S, Grady D, Bush T. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women.  JAMA. 1998;  280 605-613
• 26 Writing Group for the WHI Investigators . Risk and benefits of estrogen plus progestin in healthy postmenopausal women.  JAMA. 2002;  288 321-333
• 27 Anderson G L, Limacher M, Assaf A R. et al . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291 1701-1712
• 28 Ettinger B, Black D M, Mitlak B H. et al . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene (results from a 3-year randomized clinical trial).  JAMA. 1999;  282 637-645
• 29 Black D M, Cummings S R, Karpf D B. et al . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.  Lancet. 1996;  348 1535-1541
• 30 Cummings S R, Black D M, Thompson D E. et al . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures.  JAMA. 1998;  280 2077-2082
• 31 Bone H G, Hosking D, Devogelaer J-P. et al . Ten years' experience with alendronate for osteoporosis in postmenopausal women.  The N Engl J Med. 2004;  350 1189-1199
• 32 Harris S T, Watts N B, Genant H K. et al . Effects of Risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.  JAMA. 1999;  282 1344-1352
• 33 McClung M R, Geusens P, Miller P D. et al . Effect of risedronate on the risk of hip fracture in elderly women.  N Engl J Med. 2001;  344 333-340
• 34 Chesnut C H, Skag A, Christiansen C. et al . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.  J Bone Miner Res. 2004;  19 1241-1249
• 35 Cranney A, Tugwell P, Zytaruk N. et al . VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.  Endocr Rev. 2002;  23 540-551
• 36 Hodsman A B, Bauer D C, Dempster D. et al . Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.  Endocr Rev. 2005;  (epub ahead)
• 37 Neer R M, Arnaud C D, Zanchetta J R. et al . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.  New Engl J Med. 2001;  344 1434-1441
• 38 Ettinger B, San M J, Crans G. et al . Differential effects of Teriparatide on BMD after treatment with Raloxifene or alendronate.  J Bone Miner Res. 2004;  19 745-751
• 39 Lindsay R, Scheele W H, Neer R. et al . Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.  Arch Intern Med. 2004;  164 2024-2030
• 40 Kaufman J M, Orwoll E, Goemaere S. et al . Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.  Osteoporos Int. 2005;  16 510-516
• 41 Meunier P J, Roux C, Seeman E. et al . The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.  N Engl J Med. 2004;  350 459-468
• 42 Reginster J Y, Seeman E, De Vernejoul M C. et al . Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women: TROPOS study.  J Clin Endocrinol Metab. 2005; 
• 43 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report.  Osteoporosis Int. 1994;  4 368-381
• 44 Pfeilschifter J. Postmenopausale und Kortikoid-induzierte Osteoorose: Leitliniengerechte Prophylaxe und Therapie.  Internist. 2005;  (online 14. April)